James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals

    James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals

-- Mr. Mazzo to Help Advance Neurotech's Novel Technology --

PR Newswire

CUMBERLAND, R.I., Aug. 6, 2013

CUMBERLAND, R.I., Aug. 6, 2013 /PRNewswire/ --Neurotech Pharmaceuticals, a
biotechnology company developing sight-saving therapies for chronic retinal
disease, announced today that James Mazzo was appointed the company's
Executive Chairman. Mazzo, a long time leader in the ophthalmic industry, is
the former CEO of Abbott Medical Optics (AMO), is an Operating Partner at
Versant Ventures and was recently named Chairman and CEO of AcuFocus, a
Versant portfolio company.

(Logo: http://photos.prnewswire.com/prnh/20130806/NE59269LOGO)

As Executive Chairman, Mazzo will engage with the Neurotech team to advance
the Company's novel technology platform through the clinical development stage
toward market availability.

"Neurotech's technology is truly groundbreaking and I am confident it will
bring improved therapy to serious retinal diseases such as wet and dry
age-related macular degeneration, and macular telangiectasia – diseases that
ultimately cause blindness," said James Mazzo.

Neurotech's patented core technology platform, Encapsulated Cell Technology
(ECT), is a genetically engineered implant that enables the continuous
delivery of protein drugs directly into the vitreous of the eye. The Company
has demonstrated that a single living ECT implant can treat a diseased retina
for two years or more, thereby eliminating the need for monthly injections,
the conventional approach to treating retinal disease. ECT systems can
produce all classes of modern biotherapeutic drugs, including peptides,
hormones, monoclonal antibodies, antibody fragments and next generation
alternative scaffolds. As a robust technology platform, ECT can be adapted to
also generate protein drugs targeting uveitis, glaucoma and other ophthalmic

"I admire Jim's commitment to and extensive accomplishments in the ophthalmic
world. We are honored to have him help lead our company as we advance
Neurotech into the next phase of growth," said Ted Danse, President and CEO of

Jim Mazzo's 35-year career in the healthcare industry includes seven years as
Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold
to Abbott Labs in 2009 for $2.8 billion. He was previously with Allergan for
over 20 years in a variety of expanding roles, working and living in the U.S.,
England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002,
expanding the business into a $1 billion industry-leading, publicly-traded
corporation. Most recently, he has served as Senior Vice President, Abbott
Laboratories and President, Abbott Medical Products.

William J. Link, PhD, Managing Director at Versant Ventures and a Neurotech
board member, said, "Jim's talents are tremendously applicable to Neurotech.
We look forward to working together to further Neurotech's promising
technology in the treatment of retinal diseases and help people retain their

About Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic
retinal diseases. Utilizing its transformational technology, Encapsulated
Cell Technology (ECT), Neurotech is developing intraocular implants that
provide controlled, sustained and long-term delivery of therapeutic proteins
to the back of the eye, thereby overcoming a major obstacle in the treatment
of retinal disease. The Company's lead ECT-based product candidates include
NT-503 for the treatment of wet AMD (Phase 2), and Renexus^® (NT-501) for the
treatment of Macular Telangiectasia (pre-Phase 2). To learn more, please
visit www.neurotechusa.com.

SOURCE Neurotech USA

Website: http://www.neurotechusa.com/
Contact: Rich Small, Vice President, Chief Financial Officer, Neurotech
Pharmaceuticals, Inc., r.small@neurotechusa.com, (401) 495-2403
Press spacebar to pause and continue. Press esc to stop.